![]() Gain Therapeutics Gain Therapeutics is a biotech company that targets lysosomal enzymes to develop drugs for pediatric genetic and selected central nervous system disorders. | ![]() UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | ||
Founding Date | Founding Date 2017 | Founding Date 1928 | Founding Date 1929 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Bethesda, US HQ Barcelona, ES Lugano, CH | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more |
Employees | Employees 2321% decrease | Employees 9,052 | Employees 5,358 |
Valuation ($) | Valuation ($) 65.6 m | Valuation ($) 34.3 b | Valuation ($) 10.2 b |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) €3.7b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) | Cost of goods €659.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit €7.2b (FY, 2025) | Gross profit €3.3b (FY, 2025) |
Net income | Net income ($20.2m) (FY, 2025) | Net income €1.6b (FY, 2025) | Net income €445.1m (FY, 2025) |

UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company